Clinical trial

Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects

NCT01113320

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Safinamide Normalized identity: safinamideView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2010-04-01

PhasePHASE2

Conditions

Parkinson's Diseaseverified · MONDO: Parkinson disease

Interventions

PlaceboDRUG

SafinamideDRUG · verified · RxNorm: safinamide

Sponsors & collaborators

Newron Pharmaceuticals SPAlead sponsor

Mapped research locations

JohannesburgSouth Africa2 BerlinGermany1 ToulouseFrance1 LilleFrance1 GrazAustria1 DüsseldorfGermany1 QuébecCanada1 PretoriaSouth Africa1 BochumGermany1 InnsbruckAustria1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01113320 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.